Veerhealth Care Ltd has received approval from the United States Food and Drug Administration (USFDA) for its Drug (OTC) products, enabling the company to export to the U.S. market. The approval, granted in June 2025, follows the successful completion of a USFDA audit in April 2025. This development positions the small-cap entity to compete with larger players and attract high-volume export orders, aligning with its "LOCAL to GLOBAL" vision.

The company reported revenue of ₹16.76 crore for the fourth quarter of the fiscal year 2026 (Q4FY26), compared to ₹5.62 crore in the corresponding period of the previous year. For the full fiscal year 2025-26, revenue stood at ₹32.48 crore, up from ₹16.87 crore in FY24-25. The financial results reflect the impact of the company's expanded operations and strategic focus on the pharmaceutical and cosmetic manufacturing sectors.

Operational Expansion and Strategic Partnerships

To support its export ambitions, Veerhealth Care has expanded and upgraded its manufacturing facilities to meet USFDA standards. The company recently onboarded a leading FMCG company operating in the domestic and international markets within the 'personal and household care' segment. This partner is part of a 125-year-old prominent business group, which is expected to contribute to future revenue growth.

The company operates a manufacturing facility with a built-up area of 90,000 sq. ft. and specializes in producing Pure Vegetarian toothpaste and cosmetic products. Its manufacturing capacity includes equipment such as ContraMixers and Oral Liquid Tanks, while its filling and packaging capabilities can handle up to 0.75 million tubes per month.

Financial Performance and Projections

Veerhealth Care's net profit for Q4FY26 was ₹0.40 crore, a turnaround from a loss of ₹-0.10 crore in the same quarter of the previous year. For the full year FY25-26, the company reported a total comprehensive income of ₹0.39 crore. Management has provided projections for the upcoming fiscal years, estimating net sales of ₹102.98 crore and ₹152.47 crore for the next two periods respectively.

Financial Highlights (Amount in ₹ Crore)

The company's product portfolio includes the Ayuveer brand, covering hair care, skin care, and oral care segments. Ayuveer products are available on e-commerce platforms such as Myntra, Amazon, Nykaa, and Flipkart. Additionally, Veerhealth Care offers contract manufacturing, private label services, and custom formulation to various clients.

Veerhealth Care Limited has secured a repeat order worth ₹3.60 crores from a leading FMCG company for the supply of face care products. The order, announced on June 10, 2026, is scheduled for execution within 45 days. This contract reinforces the company's position in the skincare segment and contributes to its revenue targets for the financial year.

The buyer is a leading FMCG company operating in domestic and international markets within the 'personal and household care' segment. This entity is part of a 125-year-old prominent business group. Veerhealth Care clarified that the promoter, promoter group, or group companies hold no interest in the awarding entity, and the transaction does not fall within related party transactions.

Order Details

Financial Outlook

For FY 2026-27, Veerhealth Care expects total revenues of ₹70-75 crores with a PAT of 7-10%. The company stated that considering the current order book and ongoing discussions for orders with domestic and export buyers, it may exceed this revenue projection. Additionally, the company anticipates reaching a revenue of ₹100 crores with a PAT of 10% within the next 24 months.

Veerhealth Care Limited specializes in manufacturing pure vegetarian toothpaste and operates under the Ayuveer brand. The company highlighted that very few small-cap companies globally have secured USFDA plant clearance, positioning it in a distinctive category.